Alkermes plc

Alkermes is a biopharmaceutical company. Co.'s products include: ARISTADA, which is an extended-release injectable suspension for the treatment of schizophrenia; VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence; INVEGA SUSTENNA/XEPLION, and RISPERDAL CONSTA, which is for the treatment of schizophrenia and for the treatment of schizoaffective disorder; AMPYRA/FAMPYRA, which is a treatment to improve walking in adults with multiple sclerosis; and BYDUREON is for the treatment of type 2 diabetes. Co.'s product candidate include Aripiprazole Lauroxil Two-Month Dose for the treatment of schizophrenia, among others.
  • TickerALKS
  • ISINIE00B56GVS15
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryIreland

Analysts

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

Alkermes, Inc.: Expenses ramping up to support key products and upcoming launches, but liquidity is strong

Our credit view that negative earnings will continue, but asset coverage and liquidity remain strong and healthy top-line growth will continue.

Moody's announces completion of a periodic review of ratings of Alkermes, Inc.

Announcement: Moody's announces completion of a periodic review of ratings of Alkermes, Inc.. Global Credit Research- 15 Feb 2019. New York, February 15, 2019-- Moody's Investors Service has completed a periodic review of the ratings of Alkermes, Inc. and other ratings that are associated with the same analytical unit.

Alkermes, Inc.: Update to discussion of key credit factors

Our credit view that negative earnings will continue, but asset coverage and liquidity remain strong and healthy top-line growth will continue.

Moody's assigns Ba3 to Alkermes' term loan; stable outlook

Moody's Investors Service ("Moody's") assigned a Ba3 rating to the new senior secured term loan of Alkermes, Inc., a subsidiary of Alkermes plc (collectively "Alkermes.") There are no changes to Alkermes' existing ratings including the Ba3 Corporate Family Rating, the Ba3-PD ...

Alkermes LGD Report 2017

This document consists of file spreadsheets/PBC_1083346. xlsx.

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

ValuEngine Rating and Forecast Report for ALKS

MarketLine Department

AdheraTherapeutics - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's AdheraTherapeutics Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by AdheraTherapeutics since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. K...

MarketLine Department

Alkermes plc – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Summary Pharmaceuticals and Healthcare Key Findings Pharmaceuticals and Healthcare Pharmaceuticals and Healthcare Reasons To Buys MarketLine Key Highlights Ireland

ResearchPool Subscriptions

Get the most out of your insights

Get in touch